

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jul 2026

### Comparison Efficiency of Six-Weeks Versus Twelve-Weeks Administration of Clindamycin and Ciprofloxacin in Treatment of Diabetic Foot Osteomyelitis Without Surgical Indication

#### Protocol summary

##### Summary

(1) Objectives: Comparison efficiency of six-weeks versus twelve-weeks administration of clindamycin and ciprofloxacin in treatment of diabetic foot osteomyelitis without surgical indication based on the size of the wound, some biochemical and hematology parameters, bone probe test, culture of wound secretion, age and gender of patients, common aerobic bacterial causes of osteomyelitis and determine the antibiotic resistance of common bacterial causes of osteomyelitis in the studied population. (2) Design: The study will be intervention (experimental), including 30 patients with diabetic foot osteomyelitis without surgical indication consulted to diabetes clinic of Imam Khomeini hospital and hospitalized cases in the internal sector of there. (3) Setting and conduct: samples will be equally divided into the 6 and 12 weeks of treatment with antibiotics (ciprofloxacin + clindamycin) groups. All of the obtained variables will be classified according to the recovery or non-recovery status of patients. (4) Participants including major eligibility criteria: including criteria: confirmation of osteomyelitis in patients with diabetic foot; the absence of obesity, chronic systemic diseases and drug resistance to ciprofloxacin and clindamycin, and exclusion criteria included: the need surgical intervention at any time of the study, the presence of any of the disorders during the study follow-up and treatment of diseases, resistance of the causes against to the used antibiotics, lack of anterior and posterior leg pulses, and pregnancy. (5) Intervention: The intervention will be done when 6 or 12 weeks. (6) Main outcome measures (variables): they will be lower ESR and leukocytosis, and wound healing.

#### General information

##### Acronym

DFO

##### IRCT registration information

IRCT registration number: **IRCT2016110830793N1**

Registration date: **2017-04-08, 1396/01/19**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2017-04-08, 1396/01/19

##### Registrant information

###### Name

Elnaz Afrozeh

###### Name of organization / entity

Ardabil Medical University

###### Country

Iran (Islamic Republic of)

###### Phone

+98 41 3381 2998

###### Email address

e.afrozeh@arums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Dr. Shahram Habib Zadeh, Vice Chancellor for Research, Ardabil University of Medical Sciences. Address: End of University Avenue, Office Complex Medical University, Vice Chancellor for Research, Ardabil University of Medical Sciences, Ardabil, Tel: 00984533522089, Email: research@arums.ac.ir.

##### Expected recruitment start date

2016-05-21, 1395/03/01

##### Expected recruitment end date

2016-09-20, 1395/06/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
Comparison Efficiency of Six-Weeks Versus Twelve-Weeks Administration of Clindamycin and Ciprofloxacin in Treatment of Diabetic Foot Osteomyelitis Without Surgical Indication

**Public title**  
Efficiency of Clindamycin and Ciprofloxacin in Treatment of Diabetic Foot Osteomyelitis

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
Inclusion main criteria: confirmed the diagnosis of osteomyelitis with no surgery in patients with diabetic foot; absence of chronic liver, renal, coronary arteries, anemia, rheumatism,...; absence of resistance against ciprofloxacin and clindamycin; no recent use of ciprofloxacin and clindamycin; absence of marked obesity (BMI more than 30) Exclusion main criteria: surgical intervention at any time of the study; any disorder factors during the study follow-up and treatment; absence of etiologic agents resistance against the used antibiotics; absence of posterior and anterior pulse (by arterial Doppler test); pregnancy and absence of drug gastrointestinal complications; existence of drug complication against ciprofloxacin and clindamycin during the study; resistance against ciprofloxacin and clindamycin.

**Age**  
From **30 years** old to **45 years** old

**Gender**  
Both

**Phase**  
2-3

**Groups that have been masked**  
*No information*

**Sample size**  
Target sample size: **30**

**Randomization (investigator's opinion)**  
N/A

**Randomization description**

**Blinding (investigator's opinion)**  
Not blinded

**Blinding description**

**Placebo**  
Not used

**Assignment**  
Parallel

**Other design features**  
-

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Ardabil medical university

##### Street address

End of University Avenue, Office Complex Ardabil Medical University, Ardabil, Postal Code: 85991-56189, Tel: 0984553522247-53.

##### City

Ardabil

##### Postal code

##### Approval date

2016-04-20, 1395/02/01

##### Ethics committee reference number

IR-ARUMS-REC-1395-54

## Health conditions studied

### 1

#### Description of health condition studied

Diabetic foot osteomyelitis

#### ICD-10 code

M86.8

#### ICD-10 code description

Other osteomyelitis

## Primary outcomes

### 1

#### Description

radiography

#### Timepoint

At the beginning and end of the study

#### Method of measurement

Inflammation and air in the soft tissue, cortical bone destruction, irregular margins of skin at the wound site and in chronic cases of cortical erosions-reaction Periosteal, sclerosis and sequestra.

### 2

#### Description

Hb A1c

#### Timepoint

At the beginning and end of the study

#### Method of measurement

%, chromatography

### 3

#### Description

ESR

#### Timepoint

At the beginning and every two weeks until the end of the study

#### Method of measurement

mm/hr, ESR reader

#### 4

**Description**

positive probing test

**Timepoint**

At the beginning of the study

**Method of measurement**

Touch or contact with prob

#### 5

**Description**

FBS

**Timepoint**

at least 8 hrs fasting then at the beginning and every two weeks until the end of the study

**Method of measurement**

mg/dl, autoanalyser

#### 6

**Description**

2h pp Glu

**Timepoint**

at 2 hrs after glucose administration at the beginning and every two weeks until the end of the study

**Method of measurement**

mg/dl, autoanalyser

#### 7

**Description**

creatinine

**Timepoint**

at the beginning and end of the study

**Method of measurement**

mg/dl, autoanalyser

#### 8

**Description**

albumin

**Timepoint**

at the beginning and every two weeks until the end of the study

**Method of measurement**

g/dl, autoanalyser

#### 9

**Description**

the surface and depth measure of the ulcer

**Timepoint**

at the beginning and end of the study

**Method of measurement**

mm<sup>2</sup>

#### 10

**Description**

microbial culture and antibiogram

**Timepoint**

at the beginning of the study

**Method of measurement**

S or R, culture in microbial media and biochemical test

#### 11

**Description**

Blood cell count

**Timepoint**

at the beginning and every two weeks until the end of the study

**Method of measurement**

\*10<sup>9</sup> /L, hematology cell counter

#### 12

**Description**

WBC diff count

**Timepoint**

at the beginning and every two weeks until the end of the study

**Method of measurement**

\*10<sup>9</sup> /L, hematology cell counter

#### 13

**Description**

CRP

**Timepoint**

at the beginning and every two weeks until the end of the study

**Method of measurement**

mg/dl, Nycocard

#### 14

**Description**

RBC indices: MCV, MCH, MCHC

**Timepoint**

at the beginning and every two weeks until the end of the study

**Method of measurement**

fL, pg, %, Hematology cell counter

#### 15

**Description**

BMI

**Timepoint**

at the beginning of the study

**Method of measurement**

kg/m<sup>2</sup>, determination based weight/height<sup>2</sup>

### **Secondary outcomes**

empty

### **Intervention groups**

#### 1

**Description**

Tab. ciprofloxacin 500 mg, PO, BD, 6 weeks Cap. clindamycin 300 mg, PO, TDS, 6 weeks

**Category**

Treatment - Drugs

**2**

**Description**

Tab. ciprofloxacin 500 mg, PO, BD, 12 weeks Cap.  
clindamycin 300 mg, PO, TDS, 12 weeks

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Diabetes Clinic of Ardabil Imam Khomeini Hospital

**Full name of responsible person**

Mahnaz Ghannadi Asl

**Street address**

Ardabil Imam Khomeini Hospital, Ataei St., Ardabil.

**City**

Ardabil

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Vice Chancellor for Research, Ardabil University of  
Medical Sciences

**Full name of responsible person**

Dr.Shahram Habib Zadeh

**Street address**

End of University Avenue, Office Complex Medical  
University, Vice Chancellor for Research, Ardabil  
University of Medical Sciences, Ardabil

**City**

Ardabil

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor  
organization/entity?**

Yes

**Title of funding source**

Vice Chancellor for Research, Ardabil University of  
Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Ardabil Medical University

**Full name of responsible person**

Elnaz Afrozeh

**Position**

Resident of Internal Medicine

**Other areas of specialty/work**

**Street address**

Internal Sector of Imam Khomeini Hospital, Ardabil  
Imam Khomeini Hospital, Ataei St, Ardabil

**City**

Ardabil

**Postal code**

**Phone**

+98 45 3325 1401

**Fax**

**Email**

e.afrozeh@arums.ac.ir

**Web page address**

**Person responsible for scientific  
inquiries**

**Contact**

**Name of organization / entity**

Ardabil Medical University

**Full name of responsible person**

Manouchehr Iranparvar

**Position**

Professor of Endocrine and Metaboilc Disease

**Other areas of specialty/work**

**Street address**

Internal Sector of Imam Khomeini Hospital, Ardabil  
Imam Khomeini Hospital, Ataei St, Ardabil

**City**

Ardabil

**Postal code**

**Phone**

+98 45 3325 1401

**Fax**

**Email**

eshratkhah.behrad@gmail.com

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

I.A.U. of Shabestar Branch

**Full name of responsible person**

Behrad Eshratkhah

**Position**

PhD,Clinial Pathology

**Other areas of specialty/work**

**Street address**

I.A.U. of Shabestar Branch, Azadegan St., Shabestar

**City**

Tabriz

**Postal code**

5381637181

**Phone**

+98 41424253125

**Fax**

**Email**

eshratkhah.behrad@gmail.com;

beshratkhah@iaushab.ac.ir

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*